Skip to main content
SpringerLink
Log in

Should the beneficial impact of bezafibrate on fatty acid oxidation disorders be questioned?

  • Letter to the Editors
  • Published:
Journal of Inherited Metabolic Disease

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  • Bonnefont JP, Bastin J, Behin A, Djouadi F (2009) Bezafibrate for treatment of an inborn mitochondrial ß-oxidation defect. N Engl J Med 360:838–840

    Article  CAS  PubMed  Google Scholar 

  • Bonnefont JP, Bastin J, Laforet P et al (2010) Long-term follow-up of bezafibrate treatment in patients with the myopathic form of carnitine palmitoyltransferase 2 deficiency. Clin Pharmacol Ther 88(1):101–108

    Article  CAS  PubMed  Google Scholar 

  • Orngreen MC, Norgaard MG, Sacchetti M, van Engelen BG, Vissing J (2004) Fuel utilization in patients with very long-chain acyl-coa dehydrogenase deficiency. Ann Neurol 56(2):279–283

    Article  CAS  PubMed  Google Scholar 

  • Orngreen MC, Duno M, Ejstrup R et al (2005) Fuel utilization in subjects with carnitine palmitoyltransferase 2 gene mutations. Ann Neurol 57(1):60–66

    Article  CAS  PubMed  Google Scholar 

  • Orngreen MC, Madsen KL, Preisler N, Andersen G, Vissing J, Laforet P (2014) Bezafibrate in skeletal muscle fatty acid oxidation disorders: a randomized clinical trial. Neurology 82(7):607–613

    Article  PubMed Central  CAS  PubMed  Google Scholar 

Download references

Conflict of interest

None.

Informed consent

All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2000 (5). Informed consent was obtained from all study patients.

Author information

Authors and Affiliations

  1. INSERM UMR-S 1124, Université Paris Descartes, UFR Biomédicale des Saints-Pères 45, rue des Saints-Pères, 75270, Paris cedex 06, France

    Jean Bastin & Fatima Djouadi

  2. IHU IMAGINE (UMR1163), and Laboratoire Hospitalier de Génétique Moléculaire, Groupe Hospitalier Necker Enfants Malades, Paris, France

    Jean-Paul Bonnefont

  3. Groupe Hospitalier Necker Enfants Malades, Université Paris Descartes, Paris, France

    Jean-Louis Bresson

Authors
  1. Jean Bastin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jean-Paul Bonnefont
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Fatima Djouadi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jean-Louis Bresson
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jean Bastin.

Additional information

Communicated by: Verena Peters

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Bastin, J., Bonnefont, JP., Djouadi, F. et al. Should the beneficial impact of bezafibrate on fatty acid oxidation disorders be questioned?. J Inherit Metab Dis 38, 371–372 (2015). https://doi.org/10.1007/s10545-014-9775-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10545-014-9775-7

Keywords

Search

Navigation